Regadenoson is a selective A2A adenosine receptor agonist used as a pharmacologic stress agent in myocardial perfusion imaging (MPI). It induces coronary vasodilation, mimicking the effects of exercise in patients unable to undergo physical stress testing. Regadenoson has a rapid onset, short duration, and favorable safety profile, making it widely used in nuclear cardiology.
It is administered as a single intravenous bolus and is FDA-approved for stress testing in adults with suspected or known coronary artery disease.
Therapeutic indications include:
• Pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI)
• Evaluation of coronary artery disease in patients unable to exercise adequately
Parent: Regadenoson
Parent: Regadenoson
Parent: Regadenoson
Parent: Regadenoson
Impurities in regadenoson primarily originate from its multi-step chemical synthesis, including heterocyclic ring formation, functional group modifications, and final salt formation. As an injectable product, impurity levels are strictly regulated under ICH Q3A/B, Q3D, and USP requirements for parenteral drugs.
Process-Related Impurities
• Unreacted intermediates from purine ring synthesis
• Regioisomeric and positional isomers of adenosine derivatives
• By-products from amide coupling and alkylation steps
• Residual solvents such as acetonitrile, methanol, or DMF
• Counterion-related impurities (e.g., excess acetic acid if acetate salt used)
Degradation Impurities
• Hydrolysis of amide or ester linkages under stress conditions
• Oxidation of the purine base or side chains
• Deamination or ring-opening reactions, especially under acidic or basic pH
• Light-sensitive degradants due to the purine scaffold
Elemental Impurities
• Trace metals such as palladium, iron, or copper from catalysts or processing equipment
• Must comply with ICH Q3D thresholds for injectable products
Analytical Techniques for Impurity Detection
It is used as a pharmacologic stress agent in patients undergoing myocardial perfusion imaging who cannot exercise adequately.
It selectively activates A2A adenosine receptors in coronary arteries, leading to vasodilation and increased blood flow, simulating exercise.
Yes, due to its selective A2A activity, longer half-life, and single bolus dosing, regadenoson is often preferred over adenosine in clinical practice.
Store at 20–25°C (68–77°F) in a controlled room temperature environment, protected from light. Do not freeze.
